4-乙酰氧基-苯甲酸二烯丙基酰胺 | 100956-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 中文名称: 4-乙酰氧基-苯甲酸二烯丙基酰胺
• 英文名称: 4-acetoxy-benzoic acid diallylamide
• 英文别名: 4-Acetoxy-benzoesaeure-diallylamid；4-[Bis(prop-2-EN-1-YL)carbamoyl]phenyl acetate；[4-[bis(prop-2-enyl)carbamoyl]phenyl] acetate
• CAS: 100956-16-9
• 化学式: C₁₅H₁₇NO₃
• mdl: MFCD01195178
• 分子量: 259.305
• InChiKey: WBVRFLXJTMPEAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-乙酰氧基-苯甲酸二烯丙基酰胺 在 氢氧化钾 、 sodium hydroxide 、 potassium iodide 作用下， 生成 (4-diallylcarbamoyl-phenoxy)-acetic acid
  参考文献：
  名称：

  Construction and expression of retroviruses encoding dual drug resistance genes in human umbilical cord blood CD34+ cells

  摘要：

  A series of retroviral vectors encoding human mdr1 gene alone as well as in combination with either human mgmt gene or human mutant Ser(31)-dhfr gene are engineered. The resultant retroviruses are used to transduce human umbilical cord blood CD34(+) cells. It has been shown that expression of dual drug resistance genes in transduced cells confers a broad range of resistance to both kinds of corresponding drugs. These data suggest a rationale for the use of such double chemoresistance gene constructs in an in vivo model in which transduced hematopoietic cells will acquire multiple protection against the cytotoxic side effects of combination chemotherapy and may have future application in chemoprotection of normal tissues, thus killing tumor cells more effectively.

  DOI：

  10.1007/bf02886244

文献信息

• CURATIVES FOR EPOXY ADHESIVE COMPOSITIONS
  申请人：Dershem Stephen M.

  公开号：US20100113643A1

  公开（公告）日：2010-05-06

  The invention provides epoxy and oxetane compositions including the novel acyloxy and N-acyl curing agents described herein. Use of invention curing agents result in cured adhesive compositions with remarkably increased adhesion and reduced hydrophilicity when compared to resins cured with other types of curing agents. Furthermore, the curatives of this invention do not interfere with free-radical cure and are thus suited for use in hybrid cure thermoset compositions.

  该发明提供了包括新型酰氧基和N-酰基固化剂的环氧树脂和氧环烷组合物。使用该发明的固化剂可使胶粘剂组合物固化后的粘附性大大增加，并且与用其他类型的固化剂固化的树脂相比，其亲水性减少。此外，该发明的固化剂不会干扰自由基固化，因此适用于混合固化热固性组合物的使用。
• CURATIVES FOR EPOXY COMPOSITIONS
  申请人：Dershem Stephen M.

  公开号：US20100249276A1

  公开（公告）日：2010-09-30

  The invention provides epoxy and oxetane compositions including the novel acyloxy and N-acyl curing agents described herein. Use of invention curing agents result in cured adhesive compositions with remarkably increased adhesion and reduced hydrophilicity when compared to resins cured with other types of curing agents. Furthermore, the curatives of this invention do not interfere with free-radical cure and are thus suited for use in hybrid cure thermoset compositions.

  本发明提供了环氧和氧杂环烷组分，包括本文所述的新型酰氧基和N-酰基固化剂。使用本发明的固化剂可使固化的粘合剂组分具有显著增强的粘附性和降低的亲水性，与使用其他类型固化剂固化的树脂相比。此外，本发明的固化剂不干扰自由基固化，因此适用于混合固化热固性组分的使用。
• CURATIVES FOR EPOXY COMPOSITIONSERS
  申请人：Designer Molecules, Inc.

  公开号：US20130299747A1

  公开（公告）日：2013-11-14

  The invention provides epoxy and oxetane compositions including the novel acyloxy and N-acyl curing agents described herein. Use of invention curing agents result in cured adhesive compositions with remarkably increased adhesion and reduced hydrophilicity when compared to resins cured with other types of curing agents. Furthermore, the curatives of this invention do not interfere with free-radical cure and are thus suited for use in hybrid cure thermoset compositions.

  本发明提供了环氧和氧杂环戊烷组合物，其中包括所述的新型酰氧基和N-酰基固化剂。使用本发明的固化剂可使固化粘合剂组合物的粘附性显著增加，并且与使用其他类型的固化剂固化的树脂相比，水亲和性降低。此外，本发明的固化剂不会干扰自由基固化，因此适用于混合固化热固性组合物的使用。
• US8431655B2
  申请人：——

  公开号：US8431655B2

  公开（公告）日：2013-04-30
• Construction and expression of retroviruses encoding dual drug resistance genes in human umbilical cord blood CD34+ cells
  作者：Jun Yang、Ying Wu、Ping Ma、Yanhua Zhao、Ying You、Susan E. Kane、Ning Mao、Yangpei Zhang

  DOI：10.1007/bf02886244

  日期：2000.8

  A series of retroviral vectors encoding human mdr1 gene alone as well as in combination with either human mgmt gene or human mutant Ser(31)-dhfr gene are engineered. The resultant retroviruses are used to transduce human umbilical cord blood CD34(+) cells. It has been shown that expression of dual drug resistance genes in transduced cells confers a broad range of resistance to both kinds of corresponding drugs. These data suggest a rationale for the use of such double chemoresistance gene constructs in an in vivo model in which transduced hematopoietic cells will acquire multiple protection against the cytotoxic side effects of combination chemotherapy and may have future application in chemoprotection of normal tissues, thus killing tumor cells more effectively.